ArticleThe world journal of men's health2021
Comparison of Intralesional Hyaluronic Acid
Article in The world journal of men's health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical use of hyaluronic acid in andrology: A review.Andrology · 2022Pooled it
- Network Meta-Analysis of Different Clinical Commonly Used Drugs for the Treatment of Hypertrophic Scar and Keloid.Frontiers in medicine · 2021Pooled it
- Bridging fibrosis and function: an integrated mechanistic and therapeutic framework for Peyronie's disease and related erectile dysfunction.Sexual medicine · 2026Review
- Response to Comment on: Targeting the acute phase of Peyronie's disease: Preliminary experience with Perovial®, a novel hyaluronic acid formulation.International journal of impotence research · 2026Article
- Comment on: Targeting the acute phase of Peyronie's disease: preliminary experience with Perovial®, a novel hyaluronic acid formulation.International journal of impotence research · 2026Article
- Guideline of guidelines: Peyronie's disease.BJU international · 2026Review
- Acute Phase Peyronie's Disease: Where Do We Stand?Cureus · 2024Review
- Intralesional injection of hyaluronic acid compared with verapamil in acute phase of Peyronie's disease: A prospective randomized clinical trial.Arab journal of urology · 2024Article
- The Application of Hyaluronic Acid Injections in Functional and Aesthetic Andrology: A Narrative Review.Gels (Basel, Switzerland) · 2023Review
- Expanded Utilization of Intralesional Therapies for Treatment of Peyronie's Disease.Research and reports in urology · 2023Review
- Intralesional collagenaseTranslational andrology and urology · 2022Article
- The Natural History of Peyronie's Disease.The world journal of men's health · 2021Review
- Oral Administration and Intralesional Injection of Hyaluronic AcidThe world journal of men's health · 2021Article
- Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.Frontiers in pharmacology · 2021Review
- Efficacy of Collagenase Clostridium histolyticum (XiapexClinical drug investigation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the efficacy and safety of intralesional hyaluronic acid (HA) as compared with verapamil injection in patients with Peyronie's disease (PD). MATERIALS AND
methodsBetween January 2015 and December 2018, men in PD acute phase were prospectively recruited. This open-label, prospective study included 2 different protocols. Group A: 8-week cycle of weekly intraplaque injections with HA; Group B: 8-week cycle of weekly intraplaque injections with verapamil. Penile curvature, plaque size, International Index of Erectile Function (IIEF)-15 score and visual analogue scale (VAS) were assessed at baseline and after 3 months.
resultsTwo-hundred forty-four patients were enrolled. Of these, 125 received intralesional HA (Group A), 119 received intralesional verapamil (Group B). At enrollment, median age was 56.0 years (interquartile range [IQR]=47.0-63.0 years), median curvature 35.0° (IQR=25.0°-45.0°), median IIEF-15 score 19.0 (IQR=16.0-23.0), median VAS 4.0 (IQR=4.0-5.0). Median difference for IIEF-15 was 1.0 (95% confidence interval [CI]=1.12-1.94) in Group A and 0.0 (95% CI=-0.04-0.14) in Group B (p<0.05) and median difference for VAS score was -4.0 (95% CI=-4.11--3.65) in Group A and -1.0 (95% CI=-0.50-2.01) in Group B (p<0.05). Plaque size decreased by -1.50 mm (IQR=1.60-2.10 mm) in Group A and -1.20 in Group B (p=0.10), while penile curvature decreased by -9.50° (IQR=4.50°-13.00°) in group A and -4.50 (IQR=2.50-7.50) in Group B (p<0.01).
conclusionsIntralesional HA injections could represent a reliable treatment option for the conservative management of patients with acute phase of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.